Ironwood Pharmaceuticals Stock Forward View - Relative Strength Index
| IRWD Stock | USD 3.37 -0.01 -0.30% |
Forecasting Ironwood Pharmaceuticals' future price from a sentiment perspective requires filtering noise from signal. This module uses a structured approach to news and hype analysis to project a probable near-term direction for Ironwood Pharmaceuticals stock.
At Current evaluation date, Ironwood Pharmaceuticals reflects the 14-period RSI of 0, indicating compressed downside momentum. This extreme reading suggests selling pressure has dominated recent sessions and appears to be due for at least a temporary pause.Momentum
Sell Peaked
Oversold | Overbought |
Quarterly Earnings Growth 10.468 | EPS Estimate Next Quarter 0.15 | EPS Estimate Current Year 1.35 | EPS Estimate Next Year 1.4567 | Wall Street Target Price 6.1 |
The hype context for Ironwood Pharmaceuticals summarizes headline response alongside peer coverage. Sentiment indicators for Ironwood Pharmaceuticals are summarized using options positioning and short interest.
Short Interest Detail for Ironwood Pharmaceuticals
Short interest in Ironwood Pharmaceuticals combined with options put-to-call data provides a richer picture of aggregate bearish positioning in Ironwood than either metric alone.
200 Day MA 2.2825 | Short Percent 0.1198 | Short Ratio 4.17 | Shares Short Prior Month 11.2 M | 50 Day MA 4.2964 |
Ironwood RSI Profile
Hype vs Price Context - Ironwood Pharmaceuticals
Most equity securities that are harder to arbitrage - like Ironwood - are more sensitive to sentiment shifts. Monitoring Ironwood Pharmaceuticals' news tone over time can help investors align positions with the prevailing psychological backdrop.
Investors who incorporate Ironwood Pharmaceuticals' market sentiment into their decision-making process gain an advantage by recognizing when collective biases have pushed Ironwood Pharmaceuticals's price into overvalued or undervalued territory.
Ironwood Pharmaceuticals Implied Volatility | 2.15 |
Ironwood Pharmaceuticals' implied volatility is one of the most watched metrics in options trading. Combined with historical volatility and the current option skew, it provides a comprehensive picture of how the market perceives risk in Ironwood Pharmaceuticals shares.
Ironwood Pharmaceuticals after-hype prediction price | $ 3.36 |
This sentiment summary adds context across forecasting, technical, analyst, and earnings perspectives for the stock.
Historical Fundamental Analysis of Ironwood Pharmaceuticals provides a cross-check on projections for Ironwood Pharmaceuticals. The view supplies historical context for the projection discussion.Rule 16 Summary for current Ironwood contract - Performance Context
Rule 16 converts implied volatility into an estimated daily move of about 0.13% for 2026-05-15 options. This context is informational: with Ironwood Pharmaceuticals near $ 3.37, the daily move estimate is $ 0.004528 .
Open Interest Metrics for Ironwood 2026-05-15 Contracts
Open interest counts active Ironwood Pharmaceuticals option contracts and frames participation alongside price behavior.
Ironwood Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Ironwood price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Ironwood using various technical indicators. When you analyze Ironwood charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Check Ironwood Pharmaceuticals Volatility | Backtest Ironwood Pharmaceuticals | Information Ratio |
Ironwood Pharmaceuticals Trading Date Momentum
| On March 15 2026 Ironwood Pharmaceuticals was traded for 3.37 at the closing time. The top price for the day was 3.51 and the lowest listed price was 3.34 . There was no trading activity during the period 0.0. Lack of trading volume on March 15, 2026 did not cause price change. The trading delta at closing time against the current closing price is 0.89% . |
| Compare Ironwood Pharmaceuticals to competition |
Other Forecasting Options for Ironwood Pharmaceuticals
For any investor considering Ironwood, Ironwood Pharmaceuticals' price movement is the central factor in determining investment viability. The noise present in Ironwood Stock price charts can distort investment decisions if not properly addressed.Ironwood Pharmaceuticals Related Equities
The following equities are related to Ironwood Pharmaceuticals within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Ironwood Pharmaceuticals against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Ironwood Pharmaceuticals Market Strength Events
Market strength indicators for Ironwood Pharmaceuticals stock help investors evaluate the security's behavior relative to ongoing market conditions. These tools support better market timing and help identify entry and exit signals for Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals Risk Indicators
The analysis of Ironwood Pharmaceuticals' basic risk indicators is a key input for accurate price forecasting and sound investment decisions. Understanding the risk in Ironwood Pharmaceuticals' investment allows investors to make informed choices about accepting or mitigating that exposure.
| Mean Deviation | 3.91 | |||
| Semi Deviation | 4.73 | |||
| Standard Deviation | 5.84 | |||
| Variance | 34.13 | |||
| Downside Variance | 23.89 | |||
| Semi Variance | 22.4 | |||
| Expected Short fall | -4.41 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Ironwood Pharmaceuticals
Coverage intensity for Ironwood Pharmaceuticals matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Ironwood Pharmaceuticals Short Properties
Short sentiment tied to Ironwood Pharmaceuticals matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 177.8 M | |
| Cash And Short Term Investments | 215.5 M |
More Resources for Ironwood Stock Analysis
A structured review of Ironwood Pharmaceuticals often starts with core financial statements and trend context. Ratios and trend metrics help frame Ironwood Pharmaceuticals' operating context. Selected reports below provide context for Ironwood Stock:Historical Fundamental Analysis of Ironwood Pharmaceuticals provides a cross-check on projections for Ironwood Pharmaceuticals. The view supplies historical context for the projection discussion. Our How to Invest in Ironwood Pharmaceuticals guide offers a complete walkthrough for buying and trading Ironwood Stock.Analysis related to Ironwood Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Quarterly Earnings Growth 10.468 | Earnings Share 0.15 | Revenue Per Share | Quarterly Revenue Growth -0.47 | Return On Assets |
Market capitalization and book value offer complementary views of Ironwood Pharmaceuticals — the first driven by investor sentiment, the second by accounting standards. Ironwood Pharmaceuticals' market capitalization is 549.51 M. A P/B ratio of 2.59 indicates the market values Ironwood Pharmaceuticals above its accounting book value. Enterprise value stands at 931.85 M. Value and price for Ironwood Pharmaceuticals are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
Value and price for Ironwood Pharmaceuticals are related but not identical, and they can diverge across cycles. For Ironwood Pharmaceuticals, key inputs include a P/E ratio of 18.35, a P/B ratio of 2.59, a profit margin of 8.11%, and ROE of -5.75%. Market price reflects the current exchange level formed by active bids and offers.